회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 생명공학 > 제약
Investigation Report on China Olanzapine Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-06
분량 25 pages
서비스형태 Report
판매가격

인쇄하기

Description

According to WHO’s statistics, at least 10% of world population suffer from various kinds of mental illnesses. According to the statistics published by the National Center for Mental Health, China-CDC, the number of cases of mental illnesses is more than 100 million, among which 16 million suffer from holergasia. Mental illness has surpassed cancer and become the biggest threat to human health, ranking first in the total burden of disease in China.
As an atypical antipsychotic, olanzapine is mainly used for the treatment of the positive symtoms of schizophrenia and it also has some curative effects on schizophrenia’s negative symtoms. Developed on the base of clozapine, the former generation of antipsychotic medication, olanzapine was approved by Food and Drug Administration (FDA) to go on sale in 1996 and its patent held by Eli Lilly expired in 2011. The preparations of olanzapine available in mainland China include domestic Oulaining, Ximin and imported Zyperxa.
As a drug for schizophrenia, olanzapine entered the European and American market in 1996 and then the Chinese market in 1999. In 2003, it was even rated as the first-line drug in the Guidelines for Prevention and Control of Schizophrenia. Olanzapine develops fast after entering China, annual sales value rising from less than CNY 40 million in 2005 to CNY 420 million in 2014 and CAGR during this period reaching 30%. Hanson Pharmaceutical, Changzhou Watson Pharmaceuticals Co., Ltd and Eli Lilly and Company occupy the major market share, among which Hanson Pharmaceutical has the largest market share of about 44% for sales value in 2014.
With the change of life styles and the increased stress in work and life brought about by China’s economic development, the incidence of mental illness and psychological problems is growing. Therefore, the market size of olanzapine in China is expected to keep expanding in the next few years.

Readers can get at least the following information from this report:

-market size of olanzapine in China
-competitive landscape of olanzapine in Chinese market
-price of olanzapine made by different enterprises in China
-market outlook of olanzapine in China

The author suggests the following groups of people purchase this report:

-manufacturers of antipsychotics
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.